Early phase I study of non-viral CD19/CD22/BCMA tri-targeting JL-Lightning-CAR-T in relapsed/refractory B-cell non-Hodgkin's lymphoma.Jinxing Lou, Qijun Qian, Shuya Wang et al.|Journal of Clinical Oncology|2025Cited by 0
Lymphodepletion-free jl-lightning CAR-T targeting CD19/CD22/BCMA achieved 100% CR in 3 Relapsed/Refractory B-NHL patients: A lymphodepletion regimen comparison studyJinxing Lou, Qijun Qian, Hongfan Zhu et al.|Blood|2025Cited by 0